ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis

Since unveiling its Tecentriq monotherapy win in previously untreated non-small lung cancer, Roche has faced criticism that the diagnostic test it used to identify trial patients might have influenced its results. Not so, says a new analysis presented at the ESMO Immuno-Oncology Congress.